Close menu




November 5th, 2020 | 11:17 CET

NanoRepro, Osino Resources, Alibaba - Rich with special situations!

  • Investments
Photo credits: pixabay.com

The election outcome for the old or new President of the United States of America is taking longer than anticipated. The back and forth caused the first dip in the world stock markets yesterday until they hiked back into the green zone. The overall situation, whether Trump or Biden, hadn't changed. You can currently see a similar trend for individual stocks. After shifts or delays, stocks fall like stones, offering investors the chance of disproportionate price gains.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA68828L1004 , DE0006577109 , US01609W1027

Table of contents:


    Better late than never!

    For years, the shares of the rapid diagnostics manufacturer NanoRepro, based in Marburg an der Lahn, were bobbing along. The Company is one of the innovation leaders in the field of self-diagnostics and currently has 25 rapid tests in its portfolio - including an HIV test, two pregnancy tests and five more, purely for medical use. Then came Corona!

    Size is an advantage

    Thanks to its lean corporate structure, NanoRepro was able to react quickly and launched its first Corona antigen test at the end of September, which contributed a small six-figure sum to sales. However, the Company gave the go-ahead just under four weeks later. The test was approved by the Federal Institute for Drugs and Medical Devices (BfArM) as an antigen test for the direct detection of the coronavirus SARS-CoV-2.

    Sales explosion leads to a re-evaluation

    In 2019, the Marburg Company achieved an annual turnover of EUR 1,218,300. In comparison, the antigen test in the last two weeks of October brought in a volume of EUR 6 million. To satisfy the demand, NanoRepro offers three antigen tests from different suppliers, two of which are recognized by the Federal Institute for Drugs and Medical Devices (BfArM) and approved according to §1 Section 1 Clause 1 of the Coronavirus Test Regulation. The recognition of the third is to follow soon. We assume that the pandemic will not disappear overnight, and the strong demand for corona tests is likely to last even longer. A coup for NanoRepro!

    Outstanding projects

    The Namibian gold explorer Osino Resources has already scored a coup with its flagship project, Twin Hills Central. The area, which lies southwest of Otjikoto, has been defined so far with a length of 1.3 km. A first resource estimate is to be made here in early 2021.

    Discovery well above expectations

    The discovery drilling at Twin Hills at a depth of 65 metres and a gold grade of 1.37 grams per tonne, was so promising that the strip length has increased ten times. Several new targets have been defined along with the now 11-kilometre long gold system.

    Analysts go on purchase

    The analysts of the asset manager Echelon Capital Markets are bullish about the Company. For the Canadians, the Osino Resources share is a "top pick" for the fourth quarter of 2020 and thus a speculative buy. According to financial experts, the fair value of the Company is between CAD 2.30 and CAD 2.45. With a current share price of CAD 1.23, there is a chance that the share price will double.

    Postponed is not cancelled

    It was to be the largest IPO ever. Fintech heavyweight Ant Group wanted to raise USD 35 billion with the planned listing at a valuation of USD 200 billion, but the Shanghai Stock Exchange said "no". The group, which originated from the payment service Alipay, in which Alibaba still has a stake of about one third, would fail to meet the disclosure requirements due to changes in regulations, according to the stock exchange supervisory authority.

    Delay triggers share price collapse
    On Tuesday, Jack Ma, CEO of the parent Company Alibaba, was summoned to inform him about the temporary shutdown. After this announcement, Alibaba's shares fell by over 15% to 240 EUR from a high of 270 EUR. Of course, this decision is not final, and it would not be Jack Ma if there weren't a solution to every problem. The goal is undoubtedly to get rid of the 30% share package in the Ant Group.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read